Novartis receives FDA approval for Signifor LAR to treat acromegaly

Swiss drugmaker Novartis has received approval from US Food and Drug Administration (FDA) for its Signifor long-acting release LAR (pasireotide) for injectable suspension and intramuscular use to treat patients with acromegaly.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news